Follow
Sarat Chandarlapaty
Title
Cited by
Cited by
Year
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
22512017
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
BS Carver, C Chapinski, J Wongvipat, H Hieronymus, Y Chen, ...
Cancer cell 19 (5), 575-586, 2011
13462011
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
W Toy, Y Shen, H Won, B Green, RA Sakr, M Will, Z Li, K Gala, S Fanning, ...
Nature genetics 45 (12), 1439-1445, 2013
12842013
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ...
Cancer cell 19 (1), 58-71, 2011
10902011
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
8712018
Unlocking the potential of antibody–drug conjugates for cancer therapy
JZ Drago, S Modi, S Chandarlapaty
Nature Reviews Clinical Oncology 18 (6), 327-344, 2021
7562021
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
D Gajria, S Chandarlapaty
Expert review of anticancer therapy 11 (2), 263-275, 2011
6242011
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ...
Oncogene 30 (22), 2547-2557, 2011
6192011
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
P Lito, CA Pratilas, EW Joseph, M Tadi, E Halilovic, M Zubrowski, ...
Cancer cell 22 (5), 668-682, 2012
6162012
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
G Schiavon, S Hrebien, I Garcia-Murillas, RJ Cutts, A Pearson, ...
Science translational medicine 7 (313), 313ra182-313ra182, 2015
5952015
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ...
Cancer discovery 1 (3), 248-259, 2011
5212011
Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial
S Chandarlapaty, D Chen, W He, P Sung, A Samoila, D You, T Bhatt, ...
JAMA oncology 2 (10), 1310-1315, 2016
5012016
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing …
S Modi, A Stopeck, H Linden, D Solit, S Chandarlapaty, N Rosen, ...
Clinical Cancer Research 17 (15), 5132-5139, 2011
5012011
Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: American Society of Clinical Oncology clinical practice guideline
SH Giordano, S Temin, JJ Kirshner, S Chandarlapaty, JR Crews, ...
Journal of clinical oncology 32 (19), 2078-2099, 2014
4652014
Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway
Z Li, P Razavi, Q Li, W Toy, B Liu, C Ping, W Hsieh, F Sanchez-Vega, ...
Cancer cell 34 (6), 893-905. e8, 2018
4102018
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ...
Cell 185 (3), 563-575. e11, 2022
4012022
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ...
Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011
3902011
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C Yang, Z Li, T Bhatt, M Dickler, D Giri, M Scaltriti, J Baselga, N Rosen, ...
Oncogene 36 (16), 2255-2264, 2017
3842017
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
W Toy, H Weir, P Razavi, M Lawson, AU Goeppert, AM Mazzola, A Smith, ...
Cancer discovery 7 (3), 277-287, 2017
3722017
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ...
Science translational medicine 7 (283), 283ra51-283ra51, 2015
3602015
The system can't perform the operation now. Try again later.
Articles 1–20